Want to see VERA full AI Analyst Report?
Top Page
Vera Therapeutics
(NASDAQ:VERA)
Select Model
Select Model
Rating:53Neutral
Price Target:
$30.00
▼(-14.97% Downside)
Action:Reiterated
Date:09/15/26
Score is held back primarily by weak financial performance (no revenue history, large and worsening losses, and significant cash burn), partially offset by highly positive recent corporate milestones (FDA accelerated approval and successful Phase 3 results). Technical signals are neutral-to-mixed and valuation metrics are not very informative due to negative earnings and no dividend yield provided.
Positive Factors
Strong Phase 3 efficacy
The Phase 3 results provide meaningful evidence that TRUTAKNA may slow IgA nephropathy progression rather than merely improve a short-term laboratory measure. Durable kidney-function preservation and fewer progression events can support physician adoption, payer interest, and a stronger long-term commercial foundation.
Negative Factors
No commercial revenue
The absence of commercial revenue means Vera has not yet demonstrated a recurring sales base or a durable margin structure. Financial performance remains dependent on converting regulatory progress into sustained product demand, making execution of the launch central to future self-funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Phase 3 efficacy
The Phase 3 results provide meaningful evidence that TRUTAKNA may slow IgA nephropathy progression rather than merely improve a short-term laboratory measure. Durable kidney-function preservation and fewer progression events can support physician adoption, payer interest, and a stronger long-term commercial foundation.
Read all positive factors
Vera Therapeutics (VERA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.15B
Dividend YieldN/A
Average Volume (3M)2.29M
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS Growth-63.94%
CountryUS
Employees361
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.86
Shares Outstanding72,063,330
10 Day Avg. Volume1,872,994
30 Day Avg. Volume2,292,600
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.75
Forecast
1Y Price Target
$73.00Price Target Upside106.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-6.23
Revenue Forecast (FY)$25.17M
Vera Therapeutics Business Overview & Revenue Model
Company Description
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is at...
Vera Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 846.00K | 0.00 |
| EBITDA | -393.82M | -291.62M | -144.42M | -92.18M | -88.91M | -32.41M |
| Net Income | -401.89M | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M |
Balance Sheet | ||||||
| Total Assets | 532.98M | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M |
| Cash, Cash Equivalents and Short-Term Investments | 499.16M | 714.59M | 640.85M | 160.72M | 114.65M | 79.67M |
| Total Debt | 75.23M | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M |
| Total Liabilities | 125.23M | 130.21M | 78.53M | 73.86M | 54.53M | 14.16M |
| Stockholders Equity | 407.76M | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M |
Cash Flow | ||||||
| Free Cash Flow | -339.06M | -241.73M | -135.65M | -92.24M | -67.66M | -23.71M |
| Operating Cash Flow | -338.65M | -241.10M | -134.68M | -92.18M | -67.60M | -23.71M |
| Investing Cash Flow | 45.47M | 194.29M | -425.03M | -39.43M | -70.55M | -4.20M |
| Financing Cash Flow | 292.94M | 308.90M | 606.67M | 133.54M | 101.93M | 53.88M |
Vera Therapeutics Technical Analysis
Negative
35.28
Price Trends
32.67
Negative
34.73
Negative
38.52
Negative
Market Momentum
-1.12
Positive
38.72
Neutral
30.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Negative. The current price of 35.28 is above the 20-day moving average (MA) of 32.24, above the 50-day MA of 32.67, and below the 200-day MA of 38.52, indicating a bearish trend. The MACD of -1.12 indicates Positive momentum. The RSI at 38.72 is Neutral, neither overbought nor oversold. The STOCH value of 30.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERA.
Vera Therapeutics Risk Analysis
Vera Therapeutics disclosed 87 risk factors in its most recent earnings report. Vera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vera Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $2.22B | 7.06 | 59.00% | ― | 19.76% | 444.46% | |
58 Neutral | $1.44B | 10.38 | -109.40% | ― | ― | ― | |
53 Neutral | $2.15B | -5.10 | -84.13% | ― | ― | -63.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.78B | -2.83 | -189.68% | ― | -93.33% | -127.13% | |
45 Neutral | $915.17M | -5.23 | -49.11% | 23.67% | ― | 91.41% | |
44 Neutral | $955.83M | -1.88 | -102.97% | ― | -63.11% | 15.36% |
* Healthcare Sector Average
VERA
Vera Therapeutics
29.88
-0.61
-2.00%
OMER
Omeros
19.83
15.64
373.27%
AUPH
Aurinia Pharmaceuticals
16.65
5.55
50.00%
JBIO
Jade Biosciences
14.39
5.30
58.31%
ALMS
Alumis Inc.
7.16
2.55
55.31%
ZBIO
Zenas BioPharma, Inc.
27.26
0.72
2.71%
Vera Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Vera Therapeutics Reports Successful TRUTAKNA Phase 3 Results
Positive
Sep 15, 2026
On September 15, 2026, Vera Therapeutics reported that TRUTAKNA met all prespecified endpoints in the Phase 3 ORIGIN 3 trial in adults with primary IgA nephropathy at risk for disease progression. In the 428-patient final analysis, TRUTAKNA stabil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.